Athersys Inc (ATHXQ)

[H2R]

At June 30, 2018, we had $53.4 million in cash and cash equivalents, compared to $29.3 million at December 31, 2017.

Financing looking good (always a concern with clinical stage biotech).

Highlights:

Announced the completion of an expansion of our collaboration with HEALIOS K.K. (“Healios”) in June 2018 to develop and commercialize additional indications for $20 million in license fees, plus potential payments and royalties, which followed a $21.1 million investment by Healios in the Company’s common stock in March 2018;

Granted to Healios a time-limited first right of negotiation for an exclusive option for a license to develop and commercialize MultiStem® therapy in China for several indications;

Launched the MASTERS-2 Phase 3 registration study for ischemic stroke and enrolled initial patients into the study;

Continued to support the enrollment of Healios’ ongoing TREASURE study for ischemic stroke in Japan by providing clinical product;

Made several strategic hires, including Greg Liposky as Senior Vice President of Commercial Manufacturing to lead the execution of our manufacturing strategy;

Progressed Phase 1/2 study evaluating MultiStem therapy in acute respiratory distress syndrome (ARDS) patients, nearing enrollment completion;

Announced the award of a grant from the Medical Technology Enterprise Consortium (funded through the Department of Defense) to The University of Texas Health Science Center at Houston and Hermann Memorial Trauma Center to conduct a Phase 2 clinical trial evaluating MultiStem cell therapy for early treatment and prevention of complications after severe traumatic injury;

Recognized revenues of $19.4 million for the quarter ended June 30, 2018 and net income of $6.9 million, or $0.05 per diluted share; and
Ended the second quarter with $53.4 million of cash and cash equivalents.